Journal Information
Vol. 102. Issue 3.
Pages 212-215 (April 2011)
Share
Share
Download PDF
More article options
Vol. 102. Issue 3.
Pages 212-215 (April 2011)
Case Report
Full text access
Type I Cryoglobulinemia With a Fatal Outcome
Crioglobulinemia tipo I de desenlace fatal
Visits
5893
B. Echeverríaa,
Corresponding author
begoecheverria2@gmail.com

Corresponding author.
, M. Vitiellob, A. Abucharb, F.A. Kerdelb
a Servicio de Dermatología, Instituto Valenciano de Oncología (IVO), Valencia, Spain
b Servicio de Dermatología, Hospital de la Universidad de Miami, Florida, USA
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics
Abstract

Type I cryoglobulinemia, a condition associated with lymphoproliferative disorders, is caused by monoclonal immunoglobulins that precipitate at low temperatures. It mostly involves the skin and pathology study shows no signs of vasculitis. Management is usually based on immunosuppressive drugs associated with plasmapheresis for severe disease. The use of rituximab has recently been described for resistant cases. We present an unusual case of long-standing type I cryoglobulinemia associated with a monoclonal gammopathy of uncertain significance. The patient developed extremely severe skin lesions with histological signs of vasculitis. The patient died due to the onset of noncutaneous manifestations of the cryoglobulinemia and complications of the immunosuppressive treatment.

Keywords:
Cryoglobulinemia
Plasmapheresis
Sepsis
Resumen

La crioglobulinemia tipo I es un trastorno producido por inmunoglobulinas monoclonales que precipitan a bajas temperaturas. Se asocia a trastornos linfoproliferativos, su clínica es predominantemente cutánea y la anatomía patológica no muestra fenómenos de vasculitis. En su manejo se emplean habitualmente fármacos inmunosupresores junto con plasmaféresis para los casos graves. Recientemente se ha descrito el uso de rituximab para los casos resistentes. Se presenta un caso poco común de crioglobulinemia tipo I de largo tiempo de evolución asociada a una gammapatía monoclonal de significado incierto. El paciente desarrolló lesiones cutáneas de extrema gravedad con fenómenos de vasculitis en la anatomía patológica, y presentó un desenlace fatal secundariamente a la aparición de manifestaciones extracutáneas de la crioglobulinemia y a las complicaciones del tratamiento inmunosupresor.

Palabras clave:
Crioglobulinemia
Plasmaféresis
Sepsis
Full text is only aviable in PDF
References
[1.]
A. Tedeschi, C. Barate, E. Minola, E. Morra.
Cryoglobulinemia.
Blood Rev, 21 (2007), pp. 183-200
[2.]
G.B.J. Fernández-Herrera.
Vasculitis crioglobulinémicas.
Actas Dermosifiliogr, 94 (2003), pp. 1-10
[3.]
K. Shirato, C. Reid, J.S. Ibbetson, P. Hissaria, S. Shireen.
Diagnosis of type I cryoglobulinaemia made through identifying crystals in the blood smear.
Australas J Dermatol, 50 (2009), pp. 281-284
[4.]
A. Shaikh, T.M. Habermann, M.E. Fidler, S. Kumar, N. Leung.
Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenström's macroglobulinemia.
Clin Exp Nephrol, 12 (2008), pp. 292-295
[5.]
M. Kagaya, H. Takahashi.
A case of type I cryoglobulinemia associated with a monoclonal gammopathy of undetermined significance (MGUS).
J Dermatol, 32 (2005), pp. 128-131
[6.]
M.E. González García, C. Fernández Álvarez, V. Robles Marinas, A.J. González Huerta, M.I. Arias Miranda, A.P. González Rodríguez, et al.
[A series of 618 cases of monoclonal gammopathies of undetermined significance: predictive factors of disappearance of monoclonal component or evolution to malignant gammopathies].
Rev Clin Esp, 208 (2008), pp. 288-294
[7.]
G. Talamo, D. Claxton, G. Tricot, L. Fink, M. Zangari.
Response to bortezomib in refractory type I cryoglobulinemia.
Am J Hematol, 83 (2008), pp. 883-884
[8.]
M. Koukoulaki, S.C. Abeygunasekara, K.G. Smith, D.R. Jayne.
Remission of refractory hepatitis C-negative cryoglobulinaemic vasculitis after rituximab and infliximab.
Nephrol Dial Transplant, 20 (2005), pp. 213-216
[9.]
F. Zaja, S. De Vita, C. Mazzaro, S. Sacco, D. Damiani, G. De Marchi, et al.
Efficacy and safety of rituximab in type II mixed cryoglobulinemia.
Blood, 101 (2003), pp. 3827-3834
[10.]
G. Guhl, B. Díaz-Ley, J. Fernández-Herrera.
[Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab].
Actas Dermosifiliogr, 99 (2008), pp. 5-33
Copyright © 2011. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
Download PDF
Idiomas
Actas Dermo-Sifiliográficas
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?